Optical coherence tomography: A useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Care of patients with multiple sclerosis (MS) has evolved in the last decade to shorten the time to confirm the diagnosis of clinically definite MS and to start disease-modifying drugs as soon as possible to decrease permanent disability and the risk of progressive disease. Such trends have been achieved by improving our understanding of the role of paraclinical tests such as the presence of oligoclonal bands on CSF examination, visual evoked potentials, or MRI imaging of the brain or spinal cord. Recently, the evidence that retinal damage detected with optical coherence tomography (OCT) is a sensitive test for identifying MS-related damage in the anterior visual pathway has been added to the diagnostic armamentarium.1,2 However, symptomatic or subclinical optic nerve lesion as evidence of dissemination in space has not been included in the 2017 MS diagnostic criteria because the available data concerning the diagnostic specificity and sensitivity were considered to be insufficient to justify its inclusion at that time.3 Despite the fact that optic neuritis is one of the most characteristic findings of MS, the optic nerve has not been designated as a fifth lesion site3 because imaging and other data were unavailable to support its inclusion. Recently, Brownlee et al.4 found that the inclusion of symptomatic optic nerve involvement in patients with optic neuritis from their clinically isolated syndrome (CIS) cohort improved the accuracy of 2017 MS diagnostic criteria. This study did not include OCT. Today, evidence of optic neuritis may be confirmed clinically by visual evoked potentials or by imaging with MRI or OCT. Subclinical or oligosymptomatic cases can be confirmed with these complementary tests, and new technologies such as OCT can help to characterize the underlying conditions producing optic neuritis. Further refinement of the diagnosis of optic neuritis is now possible with the introduction of the aquaporin 4, glial fibrillary acid protein, and myelin oligodendrocyte protein antibodies, which help to exclude variants of optic nerve inflammation. Therefore, it is time to re-evaluate the inclusion of optic nerve as a fifth lesion site for dissemination in space for the diagnosis of MS.
In this issue of Neurology®, Outteryck and Lopes5 provide evidence that the presence of asymmetric retina atrophy by OCT is accurate (close to 90%) for identifying subclinical (and symptomatic) lesions in the optic nerve in patients with a first relapse of MS. They studied a prospective cohort of 130 patients with CIS (30% as optic neuritis) and identified optic nerve lesions (symptomatic and subclinical) with optic nerve MRI (3D double-inversion-recovery) as the gold standard. First, they found a significant frequency (30%) of cases with asymptomatic optic nerve lesions on MRI in patients with CIS with or without optic neuritis. They also highlight the use of the intereye asymmetry of the retinal ganglion cell layer thickness as the best method for assessing retina atrophy, as previously validated by the International Multiple Sclerosis Visual System Consortium (IMSVISUAL).1 They found that assessment of the thickness of the ganglion cell layer plus inner plexiform layer (GCIPL) is the technique that provides the highest accuracy for diagnosing optic nerve lesions (compared with the retinal nerve fiber layer and low-contrast letter acuity). They also found 2 cutoffs for diagnosing optic nerve lesions using an intereye difference of the GCIPL: (1) in the case of symptomatic optic neuritis, an intereye asymmetry of 2.83 μm had a sensitivity of 88% and specificity of 83% in establishing an optic nerve lesion; and (2) for the detection of asymptomatic optic nerve lesions, an intereye asymmetry of 1.42 μm had a sensitivity of 89% and specificity of 73%. It is important to note that other causes of optic neuritis were excluded (including idiopathic optic neuritis and anti-aquaporin or anti–myelin oligodendrocyte glycoprotein antibodies). Therefore, the patients included in this study had an optic neuritis (symptomatic and subclinical) that was typical of MS.
However, there are some limitations. At present, the resolution of OCT is in the 2- to 3-µm range, and the test-retest variability is also in the 2- to 3-μm range. Finally, healthy controls may have this level of intereye difference. However, as the authors acknowledge, prospective studies aimed at defining the risk of conversion to clinically definite MS are warranted. Furthermore, advances in OCT technology continue to improve its resolution and the analysis using machine learning tools6 and may make our measurements even more precise.
The alternative of identifying subclinical lesions in the optic nerve by MRI has limitations because the noise produced by the bone and fat can limit interpretation. A 3D double-inversion-recovery magnetic resonance sequence of the orbit is the most sensitive technique for detecting optic nerve lesions7 but can be time-consuming compared to OCT and therefore less practical and efficient in the clinical setting.
OCT has been shown to capture relevant tissue damage in the anterior optic pathway that can predict clinical outcome after optic neuritis or in chronic MS.8,–,10 OCT is now being proposed as a paraclinical tool to help establish evidence of dissemination in space for the diagnosis of MS. OCT is accessible at most of the MS centers or in collaboration with ophthalmologists. It is well tolerated by patients, is relatively inexpensive, and typically takes <5 minutes to perform. This valuable tool is now being integrated into the evaluation of patients with demyelinating diseases such as MS and neuromyelitis optica to speed the diagnosis and to support the decision-making process.
Study funding
No targeted funding reported.
Disclosure
P. Villoslada has stocks or stock options and has received consultancy fees from Bionure Farma SL, Health Engineering SL, Attune Neurosciences Inc, QMENTA Inc, CLight Inc, and NeuroPrex Inc. B. Sanchez-Dalmau is a shareholder of Bionure Farma SL and received an unrestricted grant from Bausch & Lomb and remuneration from Santhera for providing consulting services and offering lectures. S. Galetta has served as consultant to Biogen. Go to Neurology.org/N for full disclosures.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 253
- © 2020 American Academy of Neurology
References
- 1.↵
- Nolan-Kenney RC,
- Liu M,
- Akhand O, et al
- 2.↵
- 3.↵
- 4.↵
- Brownlee WJ,
- Miszkiel KA,
- Tur C,
- Barkhof F,
- Miller DH,
- Ciccarelli O
- 5.↵
- Outteryck O,
- Lopes R
- 6.↵
- Perez Del Palomar A,
- Cegonino J,
- Montolio A, et al
- 7.↵
- London F,
- Zephir H,
- Hadhoum N, et al
- 8.↵
- Sanchez-Dalmau B,
- Martinez-Lapiscina EH,
- Pulido-Valdeolivas I, et al
- 9.↵
- Sanchez-Dalmau B,
- Martinez-Lapiscina EH,
- Torres-Torres R, et al
- 10.↵
- Rothman A,
- Murphy OC,
- Fitzgerald KC, et al
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Optical coherence tomography is highly sensitive in detecting prior optic neuritisSarah Chaoying Xu, Randy H. Kardon, Jacqueline A. Leavitt et al.Neurology, January 23, 2019 -
Article
Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndromeOlivier Outteryck, Renaud Lopes, Élodie Drumez et al.Neurology, July 28, 2020 -
Drugs and Devices
The application of optical coherence tomography in neurologic diseasesRamiro S. Maldonado, Pradeep Mettu, Mays El-Dairi et al.Neurology: Clinical Practice, September 17, 2015 -
Editorial
Optic Nerve in Multiple Sclerosis Diagnostic CriteriaAn Aye to the Eyes?Wallace J. Brownlee, Steven Galetta et al.Neurology, December 16, 2020